Boehringer fol­lows the pop­u­lar KRAS trail to MD An­der­son — inks new al­liance on 'vir­tu­al' re­search cen­ter

Boehringer In­gel­heim is fol­low­ing the steadi­ly widen­ing KRAS trail to MD An­der­son.

In a new re­search pact an­nounced Mon­day morn­ing, the Ger­man phar­ma com­pa­ny says it will work with MD An­der­son in­ves­ti­ga­tors in Hous­ton to cre­ate a joint “Vir­tu­al Re­search and De­vel­op­ment Cen­ter” look­ing at two hot prospects: KRAS in­hi­bi­tion and a TRAILR2 ag­o­nis­tic an­ti­body for apop­to­sis.

KRAS has be­come a dar­ling in the can­cer R&D are­na as Am­gen has emerged as a leader in the field, tar­get­ing G12C, a pock­et on KRAS that could of­fer de­vel­op­ers a path­way to new drugs on what has long been seen as an un­drug­gable tar­get. And just a few weeks ago No­var­tis al­lied it­self with an­oth­er G12C play­er, Mi­rati, in an­oth­er in­di­ca­tion of the pop­u­lar­i­ty of KRAS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER